Effects of glipizide controlled release tablets on lipid regulation and safety in patients with new type 2 diabetes mellitus and nonalcoholic fatty liver disease
Objective To investigate the effect of glipizide controlled release tablets on the lipid-lowering effect and safety of newly diagnosed type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD). Methods 48 patients with newly diagnosed T2DM with NAFLD were enrolled in the affiliated hospital of Hangzhou normal university from September 2014 to April 2016. They were randomly divided into the control group (n=42) and the study group (n=42). The control group was treated with metformin (FPG), 2-hour postprandial blood glucose (2 hPG), total cholesterol (TC), triglyceride (TG), and total cholesterol (TC), triglyceride (TG) ), insulin resistance index (HOMA-IR) and adverse reactions were analyzed and compared. Results The total effective rate of the study group was higher than that of the control group (P<0.05). After 6 months of treatment, FPG, 2 hPG, TC, TG and HOMA-IR were significantly decreased in the study group (P<0.05). There was no significant difference in the incidence of adverse reactions (4.76%) between the study group and the control group (7.14%).There was no significant difference between the two groups. Conclusion The treatment of new T2DM with NAFLD with glipizide controlled-release tablets could be effectively reduce blood glucose, blood lipids and insulin resistance with high safety.
glipizidenew type 2 diabetes mellitusnonalcoholic fatty liverlipid regulating effectsafety
NETL
NSTL
万方数据
维普
